Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
D000799:Angioedema / Q000209:etiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D013841:Thiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011725:Pyridines; D013841:Thiazepines; C106266:omapatrilat; D015260:Neprilysin